EGFR T790M Inherited Lung Cancer Risk Study
Analysis based on 7 articles · First reported Sep 17, 2026 · Last updated Sep 22, 2026
The study could expand the addressable market for genetic testing and lung cancer screening, benefiting diagnostics companies and potentially increasing demand for EGFR-targeted therapies. It may also prompt updated screening guidelines that include genetic risk factors, creating new opportunities for pharmaceutical and biotechnology firms focused on oncology.
A study published on Sept. 17, 2026 in Science identified the inherited EGFR T790M mutation as a major risk factor for lung cancer, especially in never-smokers. Researchers led by Jaclyn LoPiccolo and Pasi A. Jänne of Dana–Farber Cancer Institute, in partnership with 23andMe, analyzed genetic and health data from more than 3.37 million people of European ancestry. Carriers of the mutation had approximately 25 times higher odds of developing lung cancer overall, and never-smokers with the mutation had roughly 62 times higher risk. The mutation was found in about 1 in 15,850 individuals overall, but was substantially more common in the Southern Appalachian region of the United States, particularly Alabama, Mississippi, and Tennessee, where prevalence reached 1 in 2,078. The variant showed no significant association with other cancers or noncancerous lung conditions. The study suggests the mutation likely arose in Europe and was brought to the U.S. by British and Irish settlers during the colonial era. The findings may inform genetic testing and lung cancer screening guidelines, which currently focus on smoking history. A clinical trial is underway to evaluate CT-based screening in mutation carriers. The research also highlights existing EGFR-targeted therapies from AstraZeneca and Johnson & Johnson, and past development efforts by Boehringer Ingelheim and Hanmi Pharm.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard